This is a StreetInsider.com Premium Only Page

(MIST) –

Apr 17, 2024 08:00 AM Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

Apr 8, 2024 04:39 PM Form 8-K Milestone Pharmaceutical For: Apr 08

Apr 8, 2024 11:36 AM Milestone Pharmaceuticals (MIST) Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at ACC

Apr 8, 2024 11:36 AM Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Apr 3, 2024 08:00 AM Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

Apr 1, 2024 08:00 AM Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Mar 28, 2024 07:07 AM Form 8-K Milestone Pharmaceutical For: Mar 28

Mar 28, 2024 07:00 AM Milestone Pharmaceuticals Inc. (MIST) Resubmits NDA for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia

Mar 28, 2024 07:00 AM Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia

Mar 21, 2024 07:22 AM Form 8-K Milestone Pharmaceutical For: Mar 21

Mar 21, 2024 07:14 AM Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Mar 21, 2024 07:02 AM Form 10-K Milestone Pharmaceutical For: Dec 31

Mar 5, 2024 03:17 PM Milestone Pharmaceuticals (MIST) PT Lowered to $5 at Piper Sandler

Mar 4, 2024 09:01 AM Form 8-K Milestone Pharmaceutical For: Feb 28

Mar 1, 2024 04:52 PM Form 424B5 Milestone Pharmaceutical

Feb 29, 2024 04:01 PM Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Feb 29, 2024 07:02 AM Milestone Pharmaceuticals Inc. (MIST) Prices 16.67M Share and Warrant Offering at $1.50/sh

Feb 29, 2024 07:00 AM Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Feb 28, 2024 05:45 PM Form 424B5 Milestone Pharmaceutical

Feb 28, 2024 04:37 PM Milestone Pharmaceuticals (MIST) Announces Proposed Share and Warrant Offering

Feb 28, 2024 04:37 PM Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Feb 26, 2024 07:07 AM Form 8-K Milestone Pharmaceutical For: Feb 26

Feb 26, 2024 07:04 AM Milestone Pharmaceuticals (MIST) Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT

Feb 26, 2024 07:00 AM Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT

Feb 14, 2024 08:56 PM Form SC 13G/A Milestone Pharmaceutical Filed by: Venrock Healthcare Capital Partners III, L.P.

Feb 14, 2024 07:11 AM Form SC 13G/A Milestone Pharmaceutical Filed by: RTW INVESTMENTS, LP

Feb 9, 2024 07:42 PM Form SC 13G/A Milestone Pharmaceutical Filed by: GOLDMAN SACHS GROUP INC

Jan 29, 2024 04:43 PM Form SC 13G/A Milestone Pharmaceutical Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Jan 24, 2024 02:29 PM Form SC 13G/A Milestone Pharmaceutical Filed by: BlackRock Inc.

Jan 18, 2024 09:00 PM MILESTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Milestone Pharmaceuticals Inc. on Behalf of Milestone Stockholders and Encourages Investors to Contact the Firm

Jan 6, 2024 03:59 PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST

Jan 1, 2024 12:35 PM ROSEN, NATIONAL TRIAL LAWYERS, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST

Dec 27, 2023 08:51 AM Milestone Pharmaceuticals (MIST) PT Lowered to $9 at TD Cowen

Dec 27, 2023 03:11 AM Milestone Pharmaceuticals Inc. (MIST) call put ratio 17calls to 1 put with focus on January 5 calls

Dec 26, 2023 04:58 PM U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.43%

Dec 26, 2023 07:16 AM Form 8-K Milestone Pharmaceutical For: Dec 26

Dec 26, 2023 07:04 AM Milestone Pharmaceuticals Inc. (MIST) to Resume Trading at 7:30 a.m.

Dec 26, 2023 07:03 AM Milestone Pharmaceuticals Inc. (MIST) Receives Refusal to File Letter from FDA for NDA for Etripamil

Dec 26, 2023 07:00 AM Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Dec 26, 2023 06:55 AM Milestone Pharmaceuticals Inc. (MIST) Halted, News Pending

Nov 21, 2023 07:00 AM Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 13, 2023 07:06 AM Form 8-K Milestone Pharmaceutical For: Nov 13

Nov 13, 2023 07:05 AM Milestone Pharmaceuticals Inc. (MIST) Tops Q3 EPS by 3c

Nov 13, 2023 06:58 AM Milestone Pharmaceuticals (MIST) Reports Q3, Provides Clinical and Corporate Updates

Nov 13, 2023 06:57 AM Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

Nov 13, 2023 06:38 AM Form 8-K Milestone Pharmaceutical For: Nov 11

Nov 13, 2023 06:10 AM Form 10-Q Milestone Pharmaceutical For: Sep 30

Nov 13, 2023 05:32 AM Milestone Pharmaceuticals Inc. (MIST) Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR

Nov 11, 2023 10:00 AM Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Nov 9, 2023 04:44 PM Form SC 13D Milestone Pharmaceutical Filed by: Alta Fundamental Advisers LLC